Los Angeles - 
(NewMediaWire) - June 22, 2021 - The Schall Law Firm, a national shareholder rights litigation firm,
announces that it is investigating claims on behalf of investors of Athira
Pharma, Inc. (“Athira” or “the Company”) (NASDAQ:
ATHA) for violations of the securities laws.
The investigation focuses on whether the Company
issued false and/or misleading statements and/or failed to disclose information
pertinent to investors. On June 17, 2021, Athira released a statement
indicating it had placed President and CEO Leen Kawas on leave and was
reviewing “actions stemming from doctoral research Dr. Kawas conducted while at
Washington State University.” Based on this news, shares of Athira plummeted by
almost 40% on June 18, 2021.
If you are a shareholder who
suffered a loss, click here to
participate.
We also encourage you to contact
Brian Schall of the Schall Law Firm, 2049
Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also
reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class in this case has not
yet been certified, and until certification occurs, you are not represented by
an attorney. If you choose to take no action, you can remain an absent class
member.
The Schall Law Firm represents
investors around the world and specializes in securities class action lawsuits
and shareholder rights litigation.
This press release may be
considered Attorney Advertising in some jurisdictions under the applicable law
and rules of ethics.
CONTACT:
The Schall
Law Firm
Brian Schall, Esq.
310-301-3335
